Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 17% revenue increase and significant cost reductions. The global restructuring is expected to save $70 million, and the company is on a path to positive cash flow. New partnerships, especially in Europe with Recordati, are promising for future revenue streams. Despite some concerns about declining margins and upfront restructuring costs, the overall outlook is optimistic with a leaner operating model and strong cash reserves. The Q&A session reinforced positive sentiment with management's focus on strategic partnerships and market expansion.
Key Financial Performance
Total net revenue $49.7 million, an increase of $7.4 million or 17% year-over-year, primarily reflecting the impact of higher U.S. sales.
Net product revenue $48.6 million, an increase of $6.7 million or 16% year-over-year. U.S. net product revenue was $40.9 million, an increase of $10.3 million or 34%, driven by an increase in net selling price from a change in customer mix and an increase in volume by regaining exclusive status with a large PBM during the quarter.
Europe business product revenue $4.1 million, consistent with the prior year period. This reflects the transition of commercialization operations to Recordati and includes $1.7 million in supply shipments to Recordati.
Rest of World business product revenue $3.6 million, a decline from the prior year but consistent with the second quarter of 2025.
Licensing and royalty revenue $1.1 million, an increase of $0.7 million year-over-year, reflecting partners continuing to drive in-market demand.
SG&A expenses $19.7 million, a reduction of $17.2 million or 47% year-over-year, reflecting the realization of savings from global restructuring.
R&D expenses $4.2 million, consistent with ongoing commitment to global regulatory support and science.
Restructuring expense $9.4 million, bringing total costs to date to $32.2 million, of which $17.2 million has been paid as of September 30, 2025.
Operating loss $11.1 million, a reduction of $14.1 million or 56% year-over-year, indicating a path to more efficient operations.
Operating margin Negative 22%, a substantial improvement from the negative 60% margin in the prior year period.
Cash and investments $286.6 million, with no debt and working capital of $446 million, supporting stability in the capital structure.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VASCEPA: Continued strong presence in the U.S. market with over 50% share of the IPE market. Regained exclusive status with a large PBM, positively impacting volumes. Demonstrated clinical efficacy in reducing cardiovascular risk, supported by inclusion in the 2025 ESC EAS dyslipidemia guideline update.
European Market Expansion: Transitioned commercialization operations to Recordati, covering nearly 100 markets globally. Recordati partnership progressing well, with knowledge transfer completed and commercialization expected to be fully managed by Recordati by the end of 2025. Sustained growth in volume and demand across European markets.
Rest of World Expansion: Partners actively expanding patient access and driving uptake of VASCEPA in key geographies. Licensing and royalty revenue increased, reflecting growing in-market demand.
Cost Savings: Implemented global restructuring, resulting in $70 million in expected OpEx savings over the next year. SG&A expenses reduced by 47% year-over-year in Q3 2025.
Financial Performance: Total net revenue increased by 17% year-over-year to $49.7 million in Q3 2025. Operating loss reduced by 56% year-over-year, with significant improvement in operating margin.
Partnership with Recordati: Shifted to a fully partnered commercial model outside the U.S., enabling efficient revenue generation and market expansion.
FDA Labeling Update: FDA revised labeling for fenofibrates, emphasizing lack of cardiovascular benefit and promoting evidence-based care. Reinforces VASCEPA's position as a proven therapy for cardiovascular risk reduction.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company faces regulatory challenges, particularly in ensuring compliance with updated FDA labeling requirements for fenofibrates. This could impact prescribing practices and market dynamics.
Market Competition: VASCEPA operates in a competitive market with generic products, requiring aggressive pricing strategies to maintain market share. This could pressure margins and revenue.
Supply Chain Transition: The transition of European commercialization operations to Recordati introduces risks related to knowledge transfer, operational handoff, and maintaining momentum during the transition phase.
Revenue Variability: The shift to a partnering model in Europe and other international markets introduces variability in product revenue, which could impact financial predictability.
Cost Management: The company is undergoing a global restructuring to reduce operating expenses, but this involves significant upfront restructuring costs and potential risks in execution.
Economic Uncertainty: Economic conditions in key markets could impact patient access and demand for VASCEPA, particularly in underpenetrated regions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
VASCEPA European Market Expansion: The company anticipates Recordati to fully manage European commercialization and promotion in all launch countries by the end of 2025. There is significant untapped potential in key European markets where VASCEPA benefits from extended patent protection until 2039.
Global Market Strategy: Amarin is actively supporting partners' initiatives to expand patient access in additional growth geographies. Partners are focused on driving patient uptake and making progress in commercialization and regulatory processes locally.
U.S. Market Dynamics: The company expects to retain major exclusive accounts at least through the end of 2025. The U.S. market is projected to remain a significant contributor of cash and profit moving forward.
Operating Margins and Cash Flow: Amarin anticipates expanded operating margins and an accelerated path to positive free cash flow over the next year, targeting 2026 for achieving positive free cash flow.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the U.S. net price trajectory for the back half of '25 and ideally into '26?
A:The U.S. net price trajectory for the remainder of 2025 is expected to remain relatively consistent with the last few quarters. For 2026, negotiations with payers are still ongoing, but historically, there has been a slight decline in net price at the beginning of the year due to contracts and agreements.
Q:What is the framework for future milestone payments from Recordati?
A:Milestone payments from Recordati are based on sales performance. Payments are triggered as sales surpass $100 million and continue to grow. Recordati is prioritizing VASCEPA and progressing quickly, though growth will take time.
Q:How should we think about the trajectory of gross margin over the next few years?
A:Gross margin percentages are expected to decline as the company moves to a partnered model. However, operating expenses will also decline, leading to benefits in operating margin over time.
Q:Do we expect 4Q '25 to mark the trough of European contribution as the transition normalizes?
A:Restructuring costs have been trending downward and are expected to continue decreasing in Q4 2025. By 2026, the transition is expected to normalize, with revenue aligning more closely with the partnership model, including variability in supply and continued royalty streams.
Q:How do we think about the split or use of fenofibrate in the U.S. versus the rest of the world, and its impact on practices?
A:In the U.S., fenofibrates are extensively used with statins for cardiovascular risk reduction, despite evidence showing no reduction in cardiovascular events and increased safety risks. The FDA has acknowledged this, and changes in provider and payer behavior could benefit VASCEPA. Globally, fenofibrates are also widely used, but the hope is that evolving science and FDA label changes will influence global practices, potentially benefiting VASCEPA.
Q:Why is the rest of the world revenue declining by half compared to 3Q 2024?
A:The decline is due to variability in supply shipments to partners, which depend on end-market demand, timing of launches, and other factors. There were additional supply purchases last year due to launches, but this quarter reflects a steady state without major launches.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about whether 4Q '25 would mark the trough of European contribution. They provided general comments about restructuring costs and normalization but did not clearly address the specific timing or details of the trough.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Berg
Burrows
ESC
FDA action
LDL
Relations portion
VASCEPA brand
account
benefit
capability
comment
compound
core
drug
event patient
expansion
fenofibrate
fibrates
finding
footprint
health care
labeling
market Recordati
market VASCEPA
market syndicate
meeting
million patient
mission
model
outcome trial
patient care
payer
portion website
practice
presence
protection potential
safety
series
statin
strength
syndicate partner
transition
triglyceride
AMRN Transcript
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call presented mixed signals. On the positive side, financial performance improved with increased revenue, gross margin, and net income. However, significant risks were highlighted, including regulatory hurdles and competitive pressures. The absence of strategic discussions and unclear management responses in the Q&A add to the uncertainty. Without additional insights into strategic initiatives or shareholder returns, the stock price is likely to remain stable, leading to a neutral rating.
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. While there are positive signs such as strong financial health and restructuring efforts leading to reduced losses, the decline in revenue across all regions and potential risks in market dynamics and regulatory approvals offset these positives. The Q&A reveals some confidence in maintaining exclusivity but lacks clarity on key strategic moves, which could cause investor uncertainty. Given these factors, the overall sentiment is neutral, with no significant catalyst for a strong stock price movement.
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call highlights strong financial performance with a 17% revenue increase and significant cost reductions. The global restructuring is expected to save $70 million, and the company is on a path to positive cash flow. New partnerships, especially in Europe with Recordati, are promising for future revenue streams. Despite some concerns about declining margins and upfront restructuring costs, the overall outlook is optimistic with a leaner operating model and strong cash reserves. The Q&A session reinforced positive sentiment with management's focus on strategic partnerships and market expansion.
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
Unknown7-30
The earnings call showed mixed signals: strong financial position and strategic partnerships, but challenges with U.S. market share and cash flow uncertainty. Revenue growth in Europe and global expansion are positives, but U.S. revenue decline and operational risks from restructuring are concerns. The Q&A revealed some uncertainty in long-term strategies, impacting sentiment. Overall, these factors balance out, leading to a neutral outlook.
AMRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
